References
- Liu B, Kerath SM, Sekeres MA, et al. Myelodysplastic syndromes spatial clusters in disease etiology and outcome. Leuk Lymphoma 2016;57: 392–399.
- Ma X, Selvin S, Raza A, et al. Clustering in the incidence of myelodysplastic syndromes. Leuk Res 2007;31:1683–1686.
- Ross ME, Wakefield J, Davis S, et al. Spatial clustering of myelodysplastic syndromes (MDS) in the Seattle-Puget Sound region of Washington State. Cancer Causes Control 2010; 21: 829–838.
- Germing U, Kobbe G, Haas R, et al. Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int 2013; 110: 783–790.
- Foran JM, Shammo JM. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. Am J Med 2012; 125(7 Suppl.): S6–S13.
- Gattermann N, Kundgen A, Kellermann L, et al. The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany. Eur J Haematol 2013; 91: 473–482.
- Pease DF, Ross JA, Poynter JN, et al. Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients. Cancer Epidemiol 2015; 39: 222–228.
- Jong KE, Smith DP, Yu XQ, et al. Remoteness of residence and survival from cancer in New South Wales. Med J Aust 2004; 180: 618–622.
- Obertova Z, Brown C, Holmes M, et al. Prostate cancer incidence and mortality in rural men – a systematic review of the literature. Rural Remote Health 2012; 12: 2039.
- Cogle CR, Iannacone MR, Yu D, et al. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk Res 2014; 38: 71–75.
- McQuilten ZK, Wood EM, Polizzotto MN, et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study. Cancer 2014; 120: 1686–1694.
- Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943–2964.